Company Overview
Snapshot
Founded in January 2023, ReadeRx Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel cancer treatments.
Business overview
ReadeRx Therapeutics is a Health Tech & Life Sciences company specializing in RNA-based cancer therapeutics. The company develops small molecule inhibitors that target the RNA binding protein IGF2BP1, which plays a pivotal role in stabilizing pro-oncogenic RNAs in various cancer types. By inhibiting IGF2BP1, ReadeRx aims to offer a novel treatment strategy for cancer, serving the pharmaceutical and healthcare industries.
Log in to access full profile ›Company Intelligence Q&A
- What is ReadeRx Therapeutics' primary focus?
- ReadeRx Therapeutics is focused on developing RNA-based cancer therapeutics, specifically small molecule inhibitors targeting the RNA binding protein IGF2BP1.
- When was ReadeRx Therapeutics founded?
- ReadeRx Therapeutics was founded in January 2023.
- What is the core technology behind ReadeRx Therapeutics' approach?
- The core technology involves developing small molecule inhibitors to target the RNA binding protein IGF2BP1, which is reactivated in many cancers and promotes pro-oncogenic processes.
- What problem does IGF2BP1 inhibition address in cancer therapy?
- IGF2BP1 is an oncofetal RNA binding protein that stabilizes key pro-oncogenic RNAs in many cancers. Its inhibition is considered a promising strategy for cancer therapy by disrupting these pro-tumorigenic processes.
- What is the current stage of ReadeRx Therapeutics' product development?
- ReadeRx Therapeutics is currently in the R&D stage for its products, focusing on developing small molecule inhibitors for cancer treatment.